Please assess the completion status of the following clinical trial:

Trial Title: A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>/=18 years of age~* chronic lymphocytic leukemia~* active CLL with progressive Binet stage B or C~* ineligible for treatment with fludarabine~* for second line patients, only pretreatment with rituximab and/or chlorambucil is allowed~* EOCG performance status \>/=2~Exclusion Criteria:~* patients who have relapsed within \<12 months of first dose of prior rituximab or chlorambucil first-line therapy~* previous or planned stem cell transplantation~* radioimmunotherapy within 6 months prior to starting study treatment~* transformation to aggressive B-cell malignancy~* any other concurrent anti-cancer therapy, or glucocorticoid \>/=20mg daily prednisolone or equivalent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).